What Does It Take to Get Men to See a Doctor?

Link: https://www.nytimes.com/2025/08/25/magazine/mens-health-doctor-masculinity.html?unlocked_article_code=1.kE8.Wnox.7wL-3zvQ9-5r&smid=url-share

Excerpt:

Right now, men in the United States, whether infants or elders, are more likely to die at younger ages than their female counterparts. Male life expectancy at birth is currently 75.8 years — 5.3 years less than it is for women. The gap between American men and women had mostly been narrowing gradually for the first decade of this century, then holding relatively steady, until the Covid-19 pandemic, when it widened sharply to 5.8 years, the largest difference since 1996. While living longer doesn’t guarantee that those extra years are healthy or meaningful, life expectancy remains a rough proxy for overall health.

Over the past several years, men have died at higher rates than women from 14 of the top 15 causes of death. The only exception has been Alzheimer’s disease — and that, at least to some extent, is because more women live long enough to develop it. Young men in particular are heavily affected by deaths of despair, like suicides and overdoses, which significantly lower overall male life expectancy. Native American and Black men have the shortest lives; across all racial groups, men die younger than women.

That disparity has many causes, one of which is that men simply don’t go to the doctor as often. The problem begins early: After pediatric care, young men largely disappear from medical settings until after serious issues arise. Women tend to see their gynecologists regularly; men have no clear equivalent. The Affordable Care Act covers only one preventive service specifically targeting men, while it lists 27 for women (some of which are related to pregnancy). HPV vaccination, for example, recommended for all adolescents, still feels mostly associated with girls, when HPV-related throat cancers are now more common in men than cervical cancers are in women.

….

By the time the man came into the E.R. where I work, the cancer had already spread throughout his body. He knew that colon cancer ran in his family, yet he didn’t get his first colonoscopy until almost a decade past the recommended time — until he decided he could no longer ignore the blood he had been seeing in his stool for a year. Work occupied his mind; besides, nothing really felt like something he couldn’t push through. After his diagnosis, surgery and chemotherapy temporarily suppressed the disease. He felt better, so he stopped seeing his doctors.

….

Around the world, in countries where precarious manhood is felt more strongly, men tend to have higher rates of risky health behaviors and lower life expectancy. Where these beliefs are strongest among the 60-plus countries surveyed, male life expectancy is about 6.7 years shorter than in countries where they are weakest — even after controlling for wealth, gender equality and number of physicians. The United States ranks higher in precarious manhood beliefs than its peers like Spain, Germany and Finland; correspondingly, American men die younger. In a forthcoming paper, researchers including Bosson and Vandello found that the more strongly a country endorses precarious manhood, the more likely its men are to die from high-risk causes — drownings, accidents, homicides — and moderate-risk causes like lung cancer from smoking.

….

American men aren’t the only ones dying younger; the life-expectancy gap between men and women exists everywhere in the world. But what is different is that other countries have done much more on a national level to try to make progress in improving men’s health. A handful, including Ireland, Australia and Brazil, have developed national men’s health policies. Since Ireland introduced its strategy in 2008 — the world’s first — it has made considerable strides in male life expectancy, outpacing most European nations. One advance the country has made is at workplaces, getting employers in male-dominated industries, like farming and construction, on board with prioritizing men’s health. “When we started this 20 years ago, we were met with a lot of resistance,” Noel Richardson, a key architect of Ireland’s men’s health plan, told me. “There’s been quite a sea change. There’s a mainstreaming and a normalizing of health for men as something we should all aspire to.”

Author(s): By Helen Ouyang
Helen Ouyang is a physician and contributing writer for the magazine.

Publication Date: 25 Aug 2025

Publication Site: NYT Magazine

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients

Link: https://jamanetwork.com/journals/jamaoncology/article-abstract/2821594

Excerpt:

Importance  Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs.

Observations  This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males.

Conclusions and Relevance  Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.

Author(s): Heather H. Cheng, MD, PhD1,2Jeffrey W. Shevach, MD3Elena Castro, MD, PhD4et al

JAMA Oncol. 2024;10(9):1272-1281.

doi:10.1001/jamaoncol.2024.2185

Publication Date: July 25, 2024

Publication Site: JAMA Oncology

Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death

Link: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2821348

Graphic:

Excerpt:

Key Points

Question  What is the colorectal cancer mortality benefit of screening with fecal immunochemical tests (FITs)?

Findings  In this nested case control study of 10 711 individuals, completing a FIT to screen for colorectal cancer was associated with a reduction in risk of dying from colorectal cancer of approximately 33% overall, and there was a 42% lower risk for left colon and rectum cancers. FIT screening was also associated with lower risk of colorectal cancer death among non-Hispanic Asian, non-Hispanic Black, and non-Hispanic White people.

Meaning  This study provides US community-based evidence that suggests FIT screening lowers the risk of dying from colorectal cancer and supports the strategy of population-based screening using FIT.

Author(s): Chyke A. Doubeni, MD, MPH1,2Douglas A. Corley, MD, PhD3Christopher D. Jensen, PhD3et al

Publication Date: July 19, 2024

Publication Site: JAMA Netw Open. 

2024;7(7):e2423671.

doi:10.1001/jamanetworkopen.2024.23671

I Am Afraid of Early Cancer Detection

Link: https://www.sensible-med.com/p/i-am-afraid-of-early-cancer-detection?utm_source=post-email-title&publication_id=1000397&post_id=141592311&utm_campaign=email-post-title&isFreemail=true&r=15zk5&utm_medium=email

Graphic:

Excerpt:

Looking a bit more closely you see why Grail’s test is actually useless, or dangerous, or both. Let’s start with the sensitivity of the test. For a cancer screening test to work, it must find disease before it has caused symptoms — when it is in an early or premalignant stage. Say what you want about lung cancer screening, mammography, PSA, and colonoscopy (I’m talking to you Drs. M and P) but at least they look for, and succeed at finding, early stage/premalignant disease. Here is the sensitivity of the Galleri test by stage: stage 1, 16.8%; stage 2, 40.4%; stage 3, 77%; stage 4, 90.1%.

The test is nearly worthless at finding stage 1 disease, the stage we would like to find with screening. The type of disease that is usually cured with surgery alone.

How about specificity? Let’s consider a fictional, 64-year-old male patient who presents to his internist worried about pancreatic cancer. I pick pancreatic not only because it is a scary cancer: we can’t screen for it, our treatments stink, and it seems to kill half the people in NYT obituary section. I also chose it because it is the anecdotal disease in the WSJ article.

….

Working through the math (prevalence 0.03%, sensitivity 61.9%, specificity 99.5%), this means our patient’s likelihood of having pancreatic cancer after a positive test is only 3.58%. For our patient, we have caused anxiety and the need for an MRI. You almost hope to find pancreatic cancer at this point to be able to say, “Well, it was all worth it.” If the MRI or ERCP is negative, the patient will live with fear and constant monitoring. (You will have to wait until next week to consider with me the impact of this test if we were to deploy it widely).

If the evaluation is positive, and you have managed to diagnose asymptomatic, pancreatic cancer, the likelihood of survival is probably, at best, 50%.

Let’s end this week with two thoughts. First the data for the Galleri test is not good, yet. The test characteristics are certainly not those we would like to see for a screening test. Even more importantly, good test characteristics are just the start. To know that a test is worthwhile, you would like to know that it does more good than harm. This has not even been tested. The WSJ article scoffs at the idea that we would want this data.5

Author(s): Adam Cifu, MD

Publication Date: 15 Feb 2024

Publication Site: Sensible Medicine, substack

Europe faces ‘cancer epidemic’ after estimated 1m cases missed during Covid

Link: https://www.theguardian.com/society/2022/nov/15/europe-faces-cancer-epidemic-after-estimated-1m-cases-missed-during-covid

Excerpt:

Experts have warned that Europe faces a “cancer epidemic” unless urgent action is taken to boost treatment and research, after an estimated 1m diagnoses were missed during the pandemic.

The impact of Covid-19 and the focus on it has exposed “weaknesses” in cancer health systems and in the cancer research landscape across the continent, which, if not addressed as a matter of urgency, will set back cancer outcomes by almost a decade, leading healthcare and scientific experts say.

A report, European Groundshot – Addressing Europe’s Cancer Research Challenges: a Lancet Oncology Commission, brought together a wide range of patient, scientific, and healthcare experts with detailed knowledge of cancer across Europe.

One unintended consequence of the pandemic was the adverse effects that the rapid repurposing of health services and national lockdowns, and their continuing legacy, have had on cancer services, on cancer research, and on patients with cancer, the experts said.

“To emphasise the scale of this problem, we estimate that about 1m cancer diagnoses might have been missed across Europe during the Covid-19 pandemic,” they wrote in The Lancet Oncology. “There is emerging evidence that a higher proportion of patients are diagnosed with later cancer stages compared with pre-pandemic rates as a result of substantial delays in cancer diagnosis and treatment. This cancer stage shift will continue to stress European cancer systems for years to come.

Author(s): Andrew Gregory

Publication Date: 15 Nov 2022

Publication Site: The Guardian UK

A colonoscopy study has some wondering if they should have the procedure. What you should know

Link: https://www.cnn.com/2022/10/10/health/colonoscopy-study-q-and-a-wellness/index.html

Excerpt:

What did this new study show about the effectiveness of colonoscopies?

In this study, about 12,000 people in Sweden, Poland and Norway got colonoscopies. They saw a 31% reduction in their risk of colon cancer and a 50% reduction in their risk of dying from colon cancer compared with people who were not invited to get a colonoscopy.

Was that about what would be expected?

Some US studies have suggested that colonoscopies are even more effective. One study followed nearly 90,000 health care professionals for 22 years. Some of them chose to receive a screening colonoscopy, and some did not. The researchers estimated that screening colonoscopy was associated with a 40% reduction in the risk of getting colon cancer and a 68% reduction in the risk of dying of colon cancer.

Why would there be different success rates in the three European countries compared with the US?

Dominitz says one reason might be that most people in the European study didn’t have sedation when they got their colonoscopies. Only 23% of the patients in the European study received sedation, but virtually everyone having a colonoscopy in the US gets it. Colonoscopies can be uncomfortable, and doctors might, without even realizing it, be less thorough if people are in pain. Thoroughness – getting the scope into the folds and crevices of the colon – is important for finding growths called polyps. The more polyps doctors are able to find, the more they can reduce the person’s risk of being diagnosed with or dying from colon cancer.

Author(s): Elizabeth Cohen

Publication Date: 11 Oct 2022

Publication Site: CNN

John Hancock to Pilot 50-Cancer Detection Test

Link: https://www.thinkadvisor.com/2022/09/20/john-hancock-to-pilot-50-cancer-detection-test/

Excerpt:

John Hancock wants to find out what happens when life insurance insureds get a blood test that might reveal early signs of about 50 different types of cancer.

The Boston-based Manulife subsidiary is working with Munich Re and other reinsurers to offer a pilot program that will pay either 50% or 100% of the cost of Grail’s Galleri cancer screening test for insureds in the John Hancock Vitality wellness program.

John Hancock will not get individual test results for the insureds who use the pilot program, nor will the program results affect the participants’ coverage, premiums or Vitality points.

Author(s): Allison Bell

Publication Date: 20 Sept 2022

Publication Site: Think Advisor